Phloroglucinol Dosing in Pediatrics
Based on available FDA labeling, phloroglucinol is dosed as three pills daily in children, taken 30 minutes after food 1. However, this represents extremely limited pediatric-specific guidance, and critical dosing parameters are absent.
Critical Evidence Gaps
The provided evidence reveals a significant lack of pediatric dosing information for phloroglucinol:
- No weight-based dosing guidelines are available in the FDA labeling
- No age-specific dose adjustments are provided beyond generic "adult or child" language 1
- No maximum single or daily dose limits are specified for pediatric patients
- No repeat interval guidance beyond "three times daily"
- The only safety guidance is to "keep out of reach of children" 1, which is standard language rather than dosing instruction
Clinical Context and Limitations
The research evidence demonstrates phloroglucinol's use in adults for:
- Abdominal pain and spasms (urinary/biliary colic) 2
- Irritable bowel syndrome at 50mg three times daily 3
- Anti-inflammatory effects through immune modulation 4
However, none of the research studies included pediatric populations for dosing determination. The systematic review 5 found insufficient evidence even for adult abdominal pain efficacy versus placebo.
Practical Approach Given Evidence Limitations
In the absence of robust pediatric dosing data, extreme caution is warranted:
- The generic "three pills daily" recommendation 1 lacks the specificity required for safe pediatric prescribing
- Without weight-based or age-stratified dosing, risk of under- or overdosing is substantial
- The pharmacokinetic data 6 shows poor systemic bioavailability and extensive metabolism, but this was studied only in adults
- General pediatric dosing principles 7 suggest drugs should be normalized to body surface area after 6 months of age, but phloroglucinol-specific data are absent
Given these limitations, phloroglucinol cannot be recommended for routine pediatric use without consulting specialized references or poison control for specific dosing guidance, as the available evidence does not provide adequate safety parameters for children.